Immuneering Corp Stock Performance
| IMRX Stock | USD 2.06 0.07 3.29% |
Immuneering Corp holds a performance score of 9 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 0.94, which attests to possible diversification benefits within a given portfolio. Immuneering Corp returns are very sensitive to returns on the market. As the market goes up or down, Immuneering Corp is expected to follow. Use Immuneering Corp maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Immuneering Corp.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Immuneering Corp are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Immuneering Corp showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.9 | Five Day Return (1.39) | Year To Date Return (70.90) | Ten Year Return (87.89) | All Time Return (87.89) |
1 | Disposition of tradable shares by Morales Mallory of Immuneering Corp subject to Rule 16b-3 | 09/11/2024 |
2 | Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Panc... | 09/12/2024 |
3 | Acquisition by Morales Mallory of 4458 shares of Immuneering Corp at 1.6235 subject to Rule 16b-3 | 09/13/2024 |
4 | Immuneering Co. to Post FY2024 Earnings of Per Share, Chardan Capital Forecasts | 09/18/2024 |
5 | Acquisition by Bookman Michael of 101116 shares of Immuneering Corp at 3.01 subject to Rule 16b-3 | 09/20/2024 |
6 | Heres Why Were A Bit Worried About Immuneerings Cash Burn Situation | 10/14/2024 |
7 | Acquisition by Feinberg Peter of 25000 shares of Immuneering Corp at 2.5485 subject to Rule 16b-3 | 10/25/2024 |
8 | Acquisition by Leah Neufeld of 60500 shares of Immuneering Corp at 6.09 subject to Rule 16b-3 | 10/31/2024 |
9 | Disposition of 60500 shares by Leah Neufeld of Immuneering Corp at 6.09 subject to Rule 16b-3 | 11/08/2024 |
10 | Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates | 11/13/2024 |
11 | Immuneering Co. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat | 11/20/2024 |
12 | Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference | 11/27/2024 |
| Begin Period Cash Flow | 72.6 M |
Immuneering |
Immuneering Corp Relative Risk vs. Return Landscape
If you would invest 121.00 in Immuneering Corp on August 31, 2024 and sell it today you would earn a total of 85.00 from holding Immuneering Corp or generate 70.25% return on investment over 90 days. Immuneering Corp is currently generating 1.2867% in daily expected returns and assumes 10.256% risk (volatility on return distribution) over the 90 days horizon. In different words, 91% of stocks are less volatile than Immuneering, and 75% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immuneering Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immuneering Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immuneering Corp, and traders can use it to determine the average amount a Immuneering Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1255
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.26 actual daily | 91 91% of assets are less volatile |
Expected Return
| 1.29 actual daily | 25 75% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Immuneering Corp is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immuneering Corp by adding it to a well-diversified portfolio.
Immuneering Corp Fundamentals Growth
Immuneering Stock prices reflect investors' perceptions of the future prospects and financial health of Immuneering Corp, and Immuneering Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immuneering Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 19.72 M | ||||
| Shares Outstanding | 31.05 M | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 563.62 X | ||||
| Revenue | 455 | ||||
| Gross Profit | 158.83 K | ||||
| EBITDA | (58.06 M) | ||||
| Net Income | (53.47 M) | ||||
| Cash And Equivalents | 128.1 M | ||||
| Cash Per Share | 4.85 X | ||||
| Total Debt | 4.46 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 33.99 X | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (48.97 M) | ||||
| Earnings Per Share | (1.97) X | ||||
| Market Capitalization | 66.14 M | ||||
| Total Asset | 102.58 M | ||||
| Retained Earnings | (163.26 M) | ||||
| Working Capital | 81.24 M | ||||
About Immuneering Corp Performance
Evaluating Immuneering Corp's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immuneering Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immuneering Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (0.59) | (0.56) |
Things to note about Immuneering Corp performance evaluation
Checking the ongoing alerts about Immuneering Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immuneering Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immuneering Corp is way too risky over 90 days horizon | |
| Immuneering Corp appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 455. Net Loss for the year was (53.47 M) with profit before overhead, payroll, taxes, and interest of 158.83 K. | |
| Immuneering Corp currently holds about 128.1 M in cash with (48.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference |
- Analyzing Immuneering Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immuneering Corp's stock is overvalued or undervalued compared to its peers.
- Examining Immuneering Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immuneering Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immuneering Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immuneering Corp's stock. These opinions can provide insight into Immuneering Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.